Literature DB >> 12970445

Differences in virus-induced cell morphology and in virus maturation between MVA and other strains (WR, Ankara, and NYCBH) of vaccinia virus in infected human cells.

Juan Carlos Gallego-Gómez1, Cristina Risco, Dolores Rodríguez, Pilar Cabezas, Susana Guerra, José L Carrascosa, Mariano Esteban.   

Abstract

Live recombinants based on attenuated modified vaccinia virus Ankara (MVA) are potential vaccine candidates against a broad spectrum of diseases and tumors. To better understand the efficacy of MVA as a human vaccine, we analyzed by confocal and electron microscopy approaches MVA-induced morphological changes and morphogenetic stages during infection of human HeLa cells in comparison to other strains of vaccinia virus (VV): the wild-type Western Reserve (WR), Ankara, and the New York City Board of Health (NYCBH) strains. Confocal microscopy studies revealed that MVA infection alters the cytoskeleton producing elongated cells (bipolar), which do not form the characteristic actin tails. Few virions are detected in the projections connecting neighboring cells. In contrast, cells infected with the WR, Ankara, and NYCBH strains exhibit a stellated (multipolar) or rounded morphology with actin tails. A detailed transmission electron microscopy analysis of HeLa cells infected with MVA showed important differences in fine ultrastructure and amounts of the viral intermediates compared to cells infected with the other VV strains. In HeLa cells infected with MVA, the most abundant viral forms are intracellular immature virus, with few intermediates reaching the intracellular mature virus (IMV) form, at various stages of maturation, which exhibit a more rounded shape than IMVs from cells infected with the other VV strains. The "IMVs" from MVA-infected cells have an abnormal internal structure ("atypical" viruses) with potential alterations in the core-envelope interactions and are unable to significantly acquire the additional double envelope to render intracellular envelope virus. The presence of potential cell-associated envelope virus is very scarce. Our findings revealed that MVA in human cells promotes characteristic morphological changes to the cells and is able to reach the IMV stage, but these virions were not structurally normal and the subsequent steps in the morphogenetic pathway are blocked.

Entities:  

Mesh:

Year:  2003        PMID: 12970445      PMCID: PMC228399          DOI: 10.1128/jvi.77.19.10606-10622.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

1.  Vaccinia virus reexamined: development and release.

Authors:  C Morgan
Journal:  Virology       Date:  1976-08       Impact factor: 3.616

2.  Two types of virus-related particles are found during transmissible gastroenteritis virus morphogenesis.

Authors:  C Risco; M Muntión; L Enjuanes; J L Carrascosa
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

3.  The vaccinia virus A27L protein is needed for the microtubule-dependent transport of intracellular mature virus particles.

Authors:  C M Sanderson; M Hollinshead; G L Smith
Journal:  J Gen Virol       Date:  2000-01       Impact factor: 3.891

4.  Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine.

Authors:  J C Ramírez; M M Gherardi; M Esteban
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

5.  Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine.

Authors:  T J Blanchard; A Alcami; P Andrea; G L Smith
Journal:  J Gen Virol       Date:  1998-05       Impact factor: 3.891

6.  The vaccinia virus 39-kDa protein forms a stable complex with the p4a/4a major core protein early in morphogenesis.

Authors:  C Risco; J R Rodríguez; W Demkowicz; R Heljasvaara; J L Carrascosa; M Esteban; D Rodríguez
Journal:  Virology       Date:  1999-12-20       Impact factor: 3.616

7.  Cellular gene expression survey of vaccinia virus infection of human HeLa cells.

Authors:  Susana Guerra; Luis A López-Fernández; Alberto Pascual-Montano; Manuel Muñoz; Keith Harshman; Mariano Esteban
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

8.  Vaccinia virus intracellular mature virions contain only one lipid membrane.

Authors:  M Hollinshead; A Vanderplasschen; G L Smith; D J Vaux
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

9.  Vaccinia virus induces Ca2+-independent cell-matrix adhesion during the motile phase of infection.

Authors:  C M Sanderson; G L Smith
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

10.  An unconventional role for cytoplasmic disulfide bonds in vaccinia virus proteins.

Authors:  J K Locker; G Griffiths
Journal:  J Cell Biol       Date:  1999-01-25       Impact factor: 10.539

View more
  19 in total

1.  Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS.

Authors:  Susana Guerra; José Manuel González; Núria Climent; Hugh Reyburn; Luis A López-Fernández; José L Nájera; Carmen E Gómez; Felipe García; José M Gatell; Teresa Gallart; Mariano Esteban
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

2.  Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene.

Authors:  José Luis Nájera; Carmen Elena Gómez; Elena Domingo-Gil; María Magdalena Gherardi; Mariano Esteban
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

3.  Host response to the attenuated poxvirus vector NYVAC: upregulation of apoptotic genes and NF-kappaB-responsive genes in infected HeLa cells.

Authors:  Susana Guerra; Luis A López-Fernández; Alberto Pascual-Montano; José Luis Nájera; Angel Zaballos; Mariano Esteban
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

Review 4.  Viruses as vaccine vectors for infectious diseases and cancer.

Authors:  Simon J Draper; Jonathan L Heeney
Journal:  Nat Rev Microbiol       Date:  2010-01       Impact factor: 60.633

5.  Differences and similarities in viral life cycle progression and host cell physiology after infection of human dendritic cells with modified vaccinia virus Ankara and vaccinia virus.

Authors:  Ann Chahroudi; David A Garber; Patrick Reeves; Luzheng Liu; Daniel Kalman; Mark B Feinberg
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

Review 6.  Therapeutic vaccination to treat chronic infectious diseases: current clinical developments using MVA-based vaccines.

Authors:  Houda Boukhebza; Nadine Bellon; Jean Marc Limacher; Geneviève Inchauspé
Journal:  Hum Vaccin Immunother       Date:  2012-08-16       Impact factor: 3.452

7.  Silencing of CDK5 reduces neurofibrillary tangles in transgenic alzheimer's mice.

Authors:  Diego Piedrahita; Israel Hernández; Alejandro López-Tobón; Dmitry Fedorov; Boguslaw Obara; B S Manjunath; Ryan L Boudreau; Beverly Davidson; Frank Laferla; Juan Carlos Gallego-Gómez; Kenneth S Kosik; Gloria Patricia Cardona-Gómez
Journal:  J Neurosci       Date:  2010-10-20       Impact factor: 6.167

8.  Modified vaccinia virus Ankara can activate NF-kappaB transcription factors through a double-stranded RNA-activated protein kinase (PKR)-dependent pathway during the early phase of virus replication.

Authors:  Heather E Lynch; Caroline A Ray; Katrina L Oie; Justin J Pollara; Ian T D Petty; Anthony J Sadler; Bryan R G Williams; David J Pickup
Journal:  Virology       Date:  2009-09-01       Impact factor: 3.616

9.  Microarray analysis reveals characteristic changes of host cell gene expression in response to attenuated modified vaccinia virus Ankara infection of human HeLa cells.

Authors:  Susana Guerra; Luis A López-Fernández; Raquel Conde; Alberto Pascual-Montano; Keith Harshman; Mariano Esteban
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

10.  In vitro host range, multiplication and virion forms of recombinant viruses obtained from co-infection in vitro with a vaccinia-vectored influenza vaccine and a naturally occurring cowpox virus isolate.

Authors:  Malachy Ifeanyi Okeke; Øivind Nilssen; Ugo Moens; Morten Tryland; Terje Traavik
Journal:  Virol J       Date:  2009-05-12       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.